Table 1.
Baseline characteristics of patients in the different subgroups.
| Patients older than 50 years | Patients with bone metastasis | |||
|---|---|---|---|---|
| Anlotinib (n=36) | Placebo (n=15) | Anlotinib (n=29) | Placebo (n=18) | |
| Age (years), n(%) | ||||
| Median Range |
58.2 53.5-63.3 |
58.5 54.3-64.3 |
53.9 49.5-59.2 |
56.1 44.1-61.0 |
| Sex, n(%) | ||||
| Male Female |
23 (63.9) 13 (36.1) |
11 (73.3) 4 (26.7) |
20 (69.0) 9 (31.0) |
9 (50.0) 9 (50.0) |
| ECOG PS, n(%) | ||||
| 0 1 |
9 (25.0) 25 (75.0) |
4 (26.7) 11 (73.3) |
11 (37.9) 18 (62.1) |
6 (33.3) 12 (66.7) |
| Surgery history, n(%) | ||||
| Yes No |
33 (91.7) 3 (8.3) |
12 (80.0) 3 (20.0) |
28 (96.5) 1 (3.5) |
16 (88.9) 2 (11.1) |
| Radiotherapy history, n(%) | ||||
| Yes No |
12 (33.3) 24 (66.7) |
4 (26.7) 11 (73.3) |
11 (37.9) 18 (62.1) |
4 (22.2) 14 (77.8) |
| Chemotherapy history, n(%) | ||||
| Yes No |
5 (13.9) 31 (86.1) |
1 (6.7) 14 (93.3) |
4 (13.8) 25 (86.2) |
3 (16.7) 15 (83.3) |
| Stage of disease, n(%) | ||||
| IVA IVB IVC |
3 (8.3) 1 (2.8) 32 (88.9) |
1 (6.7) 0 (0.0) 14 (93.3) |
1 (3.5) 1 (3.5) 27 (93.1) |
1 (5.6) 0 (0.0) 17 (94.4) |
| Liver | ||||
| Yes No |
19 (52.8) 17 (47.2) |
8 (53.3) 7 (46.7) |
18 (62.1) 11 (37.9) |
13 (72.2) 5 (27.8) |
| Lung metastasis, n(%) | ||||
| Yes No |
23 (63.9) 13 (36.1) |
11(73.3) 4 (26.7) |
17 (58.6) 12 (41.4) |
13 (72.2) 5 (27.8) |
| Lymph metastasis, n(%) | ||||
| Yes No |
32 (88.9) 4 (11.1) |
14 (93.3) 1 (6.7) |
26 (89.7) 3 (10.3) |
16 (88.9) 2 (11.1) |
| Bone metastasis, n(%) | ||||
| Yes No |
19 (52.8) 17 (47.2) |
10 (66.7) 5 (33.3) |
29 (100.0) 0 (0.0) |
18 (100.0) 0 (0.0) |